Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180294 · ClinicalTrials.gov registry record · Phase 2
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
A Phase 2 study of Breast Carcinoma and Ovarian Carcinoma, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT03180294: Completed Phase 2 study of Breast Carcinoma and Ovarian Carcinoma, sponsored by NRG Oncology.
NCT03180294 is a Phase 2 study of Breast Carcinoma and Ovarian Carcinoma that has completed, run by NRG Oncology. The registered enrollment target is 230 participants, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03180294, a Phase 2 study of Breast Carcinoma and Ovarian Carcinoma, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.
Primary Outcome
The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as "sexual desire" in the protocol.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bupropion 150 mg XL
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente-Cadillac - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente-Ontario - Ontario
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Redwood City - Redwood City
- Kaiser Permanente-Richmond - Richmond
- Kaiser Permanente-Riverside - Riverside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 2 |
What the finished NCT03180294 record still lists
NCT03180294 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 768-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (70% lower).
The record links to 7 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03180294 names 20 study sites across 1 states, led by California.
Frequently Asked Questions
What is clinical trial NCT03180294 about?
NCT03180294 is a clinical study titled "Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer". This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. Bupropion hydrochloride may work by boosting sexual desire, energy, or motivation without causing intolerable or undesirable side effects.
What is the current status of trial NCT03180294?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2017-05-31. Estimated completion is 2021-02-22.
What conditions does trial NCT03180294 study?
This clinical trial studies the following conditions: Breast Carcinoma, Ovarian Carcinoma, Cervical Carcinoma, Postmenopausal, Vulvar Carcinoma.
What interventions are being tested in trial NCT03180294?
The interventions under investigation include: Placebo (DRUG), Bupropion 150 mg XL (DRUG).
Who is sponsoring clinical trial NCT03180294?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03180294 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03180294's enrollment target sits among peer trials
230 36th of 106 higher than 70 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
RECRUITING · Phase 2
-
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
RECRUITING · Phase 2
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
RECRUITING · Phase 2
-
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI